S.Res. 97 · 113th Congress
A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the…
Full title
A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 113th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
CoburnSponsor3 cosponsors · 1 D, 2 R
2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent…
What it does: CRS summary · Introduced in Senate · Apr 15, 2013
Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
Latest action (Apr 15, 2013): Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
Policy area: Health · Origin: Senate · Introduced: Apr 15, 2013
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.